While using bridging therapy prior to CAR-T cells in myeloma, if possible, do you target a certain response prior to proceeding with cell infusion?

While CAR-T cell therapy was, of course, first studied and shown to be highly effective in heavily pretreated patients with active disease, experience and newer data show the following themes:

1. CAR-T cell therapy in earlier lines of therapy appears to lead to more durable responses.
2. Lower disease bu...

From the moment that you choose to move forward with FDA-approved CARVYKTI, you'll need to schedule immune cell collection and lymphodepletion. At my center, it takes approximately 2-4 weeks to get a collection spot during which staff works on insurance submission & approval as well as safety work-u...